A Study for Evaluate Efficacy and Safety of CAPRI cell combined first-line treatment for patients with Non-Small-Cell Lung

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019904

Enrollment

Unknown

Registered

2018-12-08

Start date

2019-03-01

Completion date

Unknown

Last updated

2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Group 1:pos-operation combined with chemotherapy

Group 2:pos-operative chemotherapy combined with CAPRI

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Histopathologically confirmed diagnosis of non-small cell lung cancer; 2. Diagnosis of patients with non-small cell lung cancer after stage IIA~IIIA; 3. Aged 18 Years to 70 Years; 4. ECOG score 0-1; 5. Patient's written informed consent; 6. Predicted survival >1 year.

Exclusion criteria

Exclusion criteria: (1) Currently participating in another clinical trial; (2) Currently participating in other immunostimulatory drugs or vaccines; (3) other immunostimulatory drugs or vaccines; (4) Clinically relevant diseases or infections (HBV, HCV, HIV); (5) Other malignant tumors; (6) Active tuberculosis (TB); (7) Drug allergic; (8) Females who are pregnant or nursing; (9) With severe viral or bacterial infections; (10) No other history of cancer. No other serious cardiopulmonary diseases, etc.

Design outcomes

Primary

Measure	Time frame
progression free survival;SAE rate;overall survival;	—

Secondary

Measure	Time frame
quality of life;	—

Countries

China

Contacts

Public ContactYi Zhang

First Affiliated Hospital, Zhengzhou University

yizhang001@163.com+86 0371-66295320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026